CONNETTIVINA PLUS 10GARZE10X10

CONNETTIVINA PLUS

active ingredients

CONNETTIVINA PLUS 2 mg/g + 10 mg/g cream 1 g cream contains 2 mg of Hyaluronic Acid Sodium Salt and 10 mg of Argentine Sulfadiazine. CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauze Every gauze of cm 10x10 is impregnated with 4 g cream containing 2 mg of Hyaluronic Acid Sodium Salt and 40 mg of Argentine Sulfadiazine. CONNETTIVINA PLUS 4 mg + 80 mg impregnated gauze Every gauze of cm 10x20 is impregnated with 8 g cream containing 4mg of Hyaluronic Acid Sodium Salt and 80 mg of Argentine Sulfadiazine. CONNETTIVINA PLUS 12 mg + 240 mg impregnated gauze Every gauze of cm 20x30 is impregnated with 24 g cream containing 12 mg of Hyaluronic Acid Sodium Salt and 240 mg of Argentine Sulfadiazine. For the full list of excipients, see paragraph 6.1.

Excellent

CONNETTIVINA PLUS 2 mg/g + 10 mg/g cream cream cream Polyethyleneglycol 400 monostearate – decilic ester of oleic acid – emulsifier wax – glycerol – 70% solution sorbitol – purified water CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauze CONNETTIVINA PLUS 4 mg + 80 mg impregnated gauze CONNETTIVINA PLUS 12 mg + 240 mg impregnated gauze Polyethyleneglycol 4000 – glycerol – purified water

Therapeutic indications

Local treatment of mild grade wounds Local treatment of I and II degree burns

Contraindications

Hypersensitivity to active ingredients and other substances closely related to chemical or any of the excipients listed in the paragraph 6.1.

Population

CONNETTIVINA PLUS 2 mg/g + 10 mg/g cream: lay a uniform layer of 2–3 mm thick cream on the entire lesion seat, one or two times a day. CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauze CONNETTIVINA PLUS 4 mg + 80 mg impregnated gauze CONNETTIVINA PLUS 12 mg + 240 mg impregnated gauze: Apply one or more medicated gauze twice or more times a day depending on the extent of injuries. Before applying CONNETTIVINA PLUS, the affected areas must be cleaned preferably with sterile physiological solution (NaCl 0.9%) and disinfected by antiseptics preferably containing hypopovidone or chlorhexidine. If necessary, surgical cleaning must be carried out. In the treatment of burns the cleaning of the lesions is preferable to be carried out with only water or sterile physiological solution avoiding disinfection with antiseptic agents before the application of Connecttivina PLUS cream or impregnated garze. After the detersion of the injured parts, lay a uniform layer of cream of 2 or 3 mm thick or apply the impregnated garzes. The application must continue until there is a possibility of infection and until complete scarring.

Conservation

Store at temperature below 30° C.

Warnings

CONNETTIVINA PLUS must be used with caution in subjects who have manifested previous allergies to sulfamidics and in the presence of liver or kidney failure.

Interactions

Local protein enzymes, applied simultaneously CONNETTIVINA PLUS, can be inactivated by the presence of silver ions. Do not simultaneously use with disinfectants containing quaternary ammonium salts as hyaluronic acid may precipitate in their presence.

Effects

After application of CONNETTIVINA PLUS, local reactions (sweet, burning, itching) may occur also of an allergic nature. Since systemic administration of sulfamidic can cause adverse reactions such as kidney failure, toxic hepatitis, agranulocytosis, thrombocytopenia and leukopenia, it cannot be ruled out that the local treatment of extensive body parts with CONNETTIVINA PLUS can give rise to undesirable effects typical of systemic sulpharidesReporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.agenziafarmaco.gov.it/it/responsabili.

Overdosing

No known overdose cases.

In the absence of data on the effects of the medicinal product on the fetus, CONNETTIVINA PLUS should not be used during pregnancy and breastfeeding unless the doctor considers that therapeutic benefits exceed the possible risks.

Source: Farmadati